Paloma Partners’s Novartis NVS Stock Holding History

Paloma Partners’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,102	Closed	-$569K	–	143
2025 Q1	$569K	Buy	+5,102	New	+$543K	0.07%	91
2022 Q1	–	Sell	-2,718	Closed	-$238K	–	2096
2021 Q4	$238K	Buy	+2,718	New	+$226K	﹤0.01%	1529
2021 Q3	–	Sell	-5,962	Closed	-$544K	–	1653
2021 Q2	$544K	Buy	+5,962	New	+$531K	0.01%	959
2021 Q1	–	Sell	-6,143	Closed	-$580K	–	2267
2020 Q4	$580K	Buy	+6,143	New	+$537K	0.02%	829
2019 Q4	–	Sell	-7,762	Closed	-$675K	–	2391
2019 Q3	$675K	Buy	7,762 +5,556	+252%	+$499K	0.01%	951
2019 Q2	$201K	Sell	2,206 -47,084	-96%	-$3.98M	﹤0.01%	1542
2019 Q1	$4.25M	Buy	+49,290	New	+$3.96M	0.1%	211
2017 Q1	–	Sell	-3,683	Closed	-$240K	–	2154
2016 Q4	$240K	Buy	+3,683	New	+$239K	﹤0.01%	1779
2016 Q1	–	Sell	-3,108	Closed	-$240K	–	2001
2015 Q4	$240K	Buy	+3,108	New	+$247K	0.01%	1467
2015 Q3	–	Sell	-2,274	Closed	-$200K	–	1813
2015 Q2	$200K	Buy	+2,274	New	+$209K	﹤0.01%	1564

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Paloma Partners's NVS Position: Q2 2025 in Review

Paloma Partners sold out of Novartis (NVS) in Q2 2025, closing a stake of 5,102 shares — an estimated $569K sold.

Paloma Partners first reported a position in NVS in Q2 2015 and held it in 10 quarters. The position peaked at $4.25M in Q1 2019. 1,383 funds tracked by Wall St. Rank hold NVS as of Q2 2025.

Paloma Partners reported no remaining Novartis position as of Q2 2025 after selling out during the quarter.
Paloma Partners sold 5,102 Novartis shares in Q2 2025, an estimated $569K.
Paloma Partners first reported a position in Novartis in Q2 2015 and held it in 10 quarters.
Paloma Partners's Novartis position peaked at $4.25M in Q1 2019.
1,383 funds tracked by Wall St. Rank held Novartis as of Q2 2025.

Based on Paloma Partners's 13F filing for Q2 2025, filed 14 Aug 2025.